Mesoblast shares (ASX: MSB) jumped sharply in yesterday’s trading session after the company announced it had achieved its target of at least 300 patients treated in a pivotal Phase 3 trial for chronic lower back pain, removing a key execution risk and clearing the path to a major regulatory catalyst.
The Mesoblast share price gain was the secured MSB its position as the second-best performer on the ASX 200 for Wednesday’s session, making the third session in four that shares have sat near the top of the daily leaderboard.
The move extends a powerful two-week rally that has seen the stock climb 27% since the start of fiscal year 2027, breaking decisively above the A$2.20-2.30 resistance zone that had capped gains for much of the previous quarter.
The Latest Leg
The latest leg of the bounce at Mesoblast was confirmation that its MSB-DR004 Phase 3 trial of rexlemestrocel-L for chronic lower back pain associated with degenerative disc disease has now treated the targeted minimum of 300 patients. The randomised, placebo-controlled study compares a single intradiscal injection of the company’s allogeneic mesenchymal precursor cell therapy with a sham procedure, following patients for 12 months to assess pain reduction, functional improvement, and opioid-sparing effects.
Top Australian Brokers
- Pepperstone - Top Australian broker - Read our review
- eToro - Invest in ASX and international shares - Read our review
Achieving the enrolment threshold removes a critical operational hurdle that had been closely watched by markets, particularly given the complexity of running large pain trials in the United States and the company’s history of regulatory setbacks in other indications.
Rexlemestrocel-L is Mesoblast’s lead asset in the chronic lower back pain space, targeting a market estimated to include millions of patients in the United States alone, many of whom are on chronic opioid therapy. The current MSB-DR004 trial is designed as a confirmatory study following an earlier 404-patient Phase 3 trial, MSB-DR003, in which the therapy demonstrated durable pain reduction and opioid-sparing benefits lasting at least two years.
The U.S. Food and Drug Administration has previously acknowledged that pain intensity outcomes in the earlier trial favoured rexlemestrocel-L, and the new study is structured to provide confirmatory evidence in the sub-population most likely to benefit. The therapy has been granted Regenerative Medicine Advanced Therapy designation by the FDA, which provides enhanced regulatory interaction and the potential for expedited review pathways.
Adding to MSB price momentum
Beyond the chronic pain program, Mesoblast has made a series of regulatory and financial moves in recent months that have bolstered sentiment around the broader platform. In early July, the company received an FDA Biologics License Application filing number and requested modular review for one of its lead cell therapy products, signalling active engagement with regulators and progress toward formal submissions.
The company also secured FDA clearance in April for an Investigational New Drug application to begin a registration-intent trial of Ryoncil in Duchenne muscular dystrophy, adding another late-stage indication to the pipeline. On the funding front, Mesoblast drew down US$50 million from a five-year non-dilutive facility in late June, extending its cash runway through key catalysts and reducing near-term dilution risk for existing shareholders.
Markets have interpreted the confluence of these developments as evidence that Mesoblast is transitioning from a company stuck in regulatory limbo to one with multiple shots on goal and a credible path to commercialisation.
Pattern Break for Mesoblast Shares?
The break above A$2.30 this week has cleared a multi-month consolidation pattern for Mesoblast shares, with the next major resistance zone sitting around the YTD break even line A$2.70-A$2.80.
The path forward for Mesoblast hinges on whether MSB-DR004 can replicate or improve upon the outcomes seen in the earlier Phase 3 trial, a question that will not be answered for at least another year. Pain trials, particularly in chronic lower back pain, have a well-documented history of high placebo response rates and late-stage failures, even for biologic therapies with promising early data.
If the confirmatory trial meets its primary endpoints and demonstrates a clinically meaningful and statistically robust benefit, Mesoblast could be positioned to file for regulatory approval in a large, underserved market with significant commercial potential and a compelling opioid-sparing narrative that aligns with public health priorities.
On the other hand, a failed or marginal outcome would likely erase much of the value that has been built into the stock over the past two weeks and force a fundamental reassessment of the company’s lead asset and overall platform value.
Bull Case:
- Pivotal CLBP trial fully enrolled, de-risking execution to major regulatory catalyst
- RMAT designation and BLA modular review signal active FDA engagement
- US$50 million non-dilutive facility extends runway through key data readouts
- Large underserved market with opioid-sparing positioning in chronic lower back pain
- Multiple late-stage programs provide diversified shots on goal across regenerative medicine
Bear Case:
- No efficacy data disclosed; binary clinical risk remains fully intact
- Pain trials notoriously difficult with high placebo rates and frequent failures
- Historical FDA setbacks elevate regulatory risk despite recent positive interactions
- Stock up 27% in two weeks, pricing in success not yet proven
- Long catalyst-free period ahead increases vulnerability to sector or macro sell-off
